274.90
+0.50
+(0.18%)
At close: January 24 at 5:31:01 PM GMT+1
Research Analysis
Earnings Estimate
Currency in USD | Current Qtr. (Sep 2024) | Next Qtr. (Dec 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
No. of Analysts | -- | -- | 18 | 18 |
Avg. Estimate | 0 | 0 | 18.67 | 20.65 |
Low Estimate | 0 | 0 | 17.17 | 19.45 |
High Estimate | 0 | 0 | 20.05 | 21.96 |
Year Ago EPS | -- | -- | 18.57 | 18.67 |
Revenue Estimate
Currency in CHF | Current Qtr. (Sep 2024) | Next Qtr. (Dec 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
No. of Analysts | 3 | 3 | 15 | 16 |
Avg. Estimate | 14.91B | 15.34B | 60.83B | 64.73B |
Low Estimate | 14.82B | 15.19B | 60.17B | 63.03B |
High Estimate | 15.07B | 15.42B | 62.19B | 66.56B |
Year Ago Sales | 14.27B | 14.66B | 58.72B | 60.83B |
Sales Growth (year/est) | 4.48% | 4.63% | 3.60% | 6.41% |
EPS Trend
Currency in USD | Current Qtr. (Sep 2024) | Next Qtr. (Dec 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
Current Estimate | 0 | 0 | 18.67 | 20.65 |
7 Days Ago | 0 | 0 | 18.8 | 20.66 |
30 Days Ago | 0 | 0 | 18.75 | 20.53 |
60 Days Ago | 0 | 0 | 18.63 | 20.41 |
90 Days Ago | 0 | 0 | 18.57 | 20.21 |
EPS Revisions
Currency in USD | Current Qtr. (Sep 2024) | Next Qtr. (Dec 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
Up Last 7 Days | -- | -- | 2 | 3 |
Up Last 30 Days | -- | -- | 5 | 7 |
Down Last 7 Days | -- | -- | 1 | -- |
Down Last 30 Days | -- | -- | 2 | -- |
Growth Estimates
Current Qtr. | Next Qtr. | Current Year | Next Year | |
---|---|---|---|---|
ROG.SW | -- | -- | 0.53% | 10.60% |
S&P 500 | 9.90% | 11.00% | 14.01% | 13.54% |
Related Tickers
NOVN.SW Novartis AG
90.26
0.00%
BAYN.DE Bayer Aktiengesellschaft
20.90
-0.85%
SAN.PA Sanofi
100.16
+0.27%
NVS Novartis AG
99.97
-0.06%
AZN.L AstraZeneca PLC
11,050.00
+0.04%
NOVO-B.CO Novo Nordisk A/S
622.40
+7.13%
SNY Sanofi
52.48
+0.96%
NOV.DE Novo Nordisk A/S
83.38
+6.79%
AZN AstraZeneca PLC
69.06
+0.67%
GSK.L GSK plc
1,356.50
-0.51%